Headquartered in Salt Lake City, UT Fiscal year ends December NASDAQ: RXRX recursion.com
Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines AI, automated laboratory infrastructure, and proprietary multimodal biological data to discover and develop novel therapeutics. The company operates an end-to-end AI-native drug discovery and development platform called the Recursion OS, which integrates biology, chemistry, and clinical development into a unified intelligence system. Recursion has generated over 50 petabytes of proprietary data from more than 300 million experiments conducted in its automated laboratories. The company has five clinical-stage programs spanning oncology and rare disease, including REC-4881 (MEK1/2 inhibitor for Familial Adenomatous Polyposis), REC-1245 (RBM39 degrader for solid tumors), REC-617 (CDK7 inhibitor), REC-3565 (MALT1 inhibitor), and REC-4539 (LSD1 inhibitor), with REC-7735 (PI3Kα H1047R inhibitor) having recently received IND clearance. Recursion maintains major collaborations with Roche/Genentech in neuroscience and with Sanofi in immunology & inflammation and oncology, having received over $500 million in total partner inflows to date. The company trades on Nasdaq under the ticker RXRX. Updated
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully…
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates…
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the…
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the great GPU kingpin Nvidia…
Joey Frenette Nvidia’s Strategic AI Vision Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has solidified its position as the backbone of the artificial intelligence (AI) revolution, with its graphics processing units (GPUs) driving the most…
Because Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has become the face of artificial intelligence, investors tend to view it as a proxy for the technology. If you want to buy into AI’s…
Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably, the flagship…
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure. While Wood formed her investment…
Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines AI, automated laboratory infrastructure, and proprietary multimodal biological data to discover and develop novel therapeutics.
The Wall Street consensus 12-month price target for RXRX is $7.22.
